Fujian Cosunter Pharmaceutical Co., Ltd. (SHE:300436)
China · Delayed Price · Currency is CNY 89.75
-1.61 (-1.76%)
Sep 4, 2026, 3:04 PM CST
SHE:300436 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 423.7 | 412.41 | 437.48 | 413.32 | 379.76 | 370.01 |
Other Revenue | 3.97 | 3.97 | 3.98 | 9.4 | 6.01 | 0.43 |
| 427.67 | 416.37 | 441.46 | 422.71 | 385.77 | 370.44 | |
Revenue Growth | -1.03% | -5.68% | 4.43% | 9.58% | 4.14% | 0.53% |
Cost of Revenue | 204.74 | 191.96 | 202.19 | 186.54 | 162.62 | 140.19 |
Gross Profit | 222.92 | 224.42 | 239.27 | 236.18 | 223.15 | 230.25 |
Selling, General & Admin | 305.04 | 314.53 | 311.75 | 304.71 | 262.65 | 234.7 |
Research & Development | 39.96 | 31.83 | 44.05 | 132.96 | 185.46 | 68.99 |
Other Operating Expenses | 9.23 | 8.57 | 7.65 | 8.8 | -0.58 | 6.85 |
Operating Expenses | 355.77 | 356.48 | 364 | 448.24 | 448.11 | 311.31 |
Operating Income | -132.85 | -132.06 | -124.74 | -212.07 | -224.96 | -81.06 |
Interest Expense | -32.85 | -32.85 | -35.55 | -35.03 | -10.59 | -9.13 |
Interest & Investment Income | 0.42 | 0.42 | 1.41 | 4.5 | 76.09 | 30.7 |
Earnings From Equity Investments | -2.68 | -3.15 | -11 | - | - | - |
Currency Exchange Gain (Loss) | -0 | -0 | 0 | 0 | -0.01 | 0 |
Other Non Operating Income (Expenses) | -0.94 | -0.24 | -0.05 | -0.23 | -3.06 | -0.11 |
EBT Excluding Unusual Items | -168.9 | -167.89 | -169.92 | -242.82 | -162.54 | -59.59 |
Gain (Loss) on Sale of Investments | -6.57 | -6.57 | - | -61.84 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 0.01 | -0.02 | - | -0.31 |
Asset Writedown | -68.73 | -63.48 | -39.77 | -0.22 | -0.88 | -1.32 |
Other Unusual Items | 8.67 | 8.67 | 45.27 | 6.87 | - | 15.54 |
Pretax Income | -235.52 | -229.25 | -164.41 | -298.03 | -163.42 | -45.69 |
Income Tax Expense | 11.93 | 12.58 | 8.06 | 76.87 | -22.86 | -11.53 |
Earnings From Continuing Operations | -247.45 | -241.83 | -172.47 | -374.9 | -140.57 | -34.16 |
Minority Interest in Earnings | 28.15 | 23.98 | 16.16 | 26.31 | 13.16 | -0.72 |
Net Income | -219.3 | -217.85 | -156.3 | -348.59 | -127.4 | -34.89 |
Net Income to Common | -219.3 | -217.85 | -156.3 | -348.59 | -127.4 | -34.89 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 159 | 159 | 159 | 159 | 159 | 149 |
Shares Outstanding (Diluted) | 159 | 159 | 159 | 159 | 159 | 149 |
Shares Change | -0.01% | 0.00% | -0.00% | 0.06% | 6.54% | 6.43% |
EPS (Basic) | -1.38 | -1.37 | -0.98 | -2.19 | -0.80 | -0.23 |
EPS (Diluted) | -1.38 | -1.37 | -0.98 | -2.19 | -0.80 | -0.23 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Free Cash Flow | -114.97 | -94.6 | -46.28 | -375.83 | -315.64 | -192.17 |
Free Cash Flow Per Share | -0.72 | -0.59 | -0.29 | -2.36 | -1.98 | -1.29 |
Gross Margin | 52.13% | 53.90% | 54.20% | 55.87% | 57.85% | 62.16% |
Operating Margin | -31.06% | -31.72% | -28.26% | -50.17% | -58.32% | -21.88% |
Profit Margin | -51.28% | -52.32% | -35.41% | -82.47% | -33.03% | -9.42% |
Free Cash Flow Margin | -26.88% | -22.72% | -10.48% | -88.91% | -81.82% | -51.88% |
EBITDA | -49.75 | -40.09 | -29.9 | -140.26 | -166.66 | -29.29 |
EBITDA Margin | -11.63% | -9.63% | -6.77% | -33.18% | -43.20% | -7.91% |
D&A For EBITDA | 83.1 | 91.98 | 94.84 | 71.81 | 58.3 | 51.77 |
EBIT | -132.85 | -132.06 | -124.74 | -212.07 | -224.96 | -81.06 |
EBIT Margin | -31.06% | -31.72% | -28.26% | -50.17% | -58.32% | -21.88% |
Revenue as Reported | 416.37 | 416.37 | 441.46 | 422.71 | - | 370.44 |